In a report released today, Raju Prasad from William Blair maintained a Buy rating on Global Blood Therapeutics (GBT). The company’s shares closed last Monday at $75.11, close to its 52-week high of $79.95.

According to, Prasad is a 5-star analyst with an average return of 25.9% and a 64.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $97.07, a 23.7% upside from current levels. In a report issued on November 25, Wells Fargo also maintained a Buy rating on the stock with a $122.00 price target.

See today’s analyst top recommended stocks >>

Based on Global Blood Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $64.55 million. In comparison, last year the company had a GAAP net loss of $43.07 million.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GBT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.

Source link